This phase II trial evaluates the effectiveness of aromatherapy for reducing nausea, vomiting, and anti-emetic use in cancer patients receiving standard of care chemotherapy treatments. Many cancer patients who receive chemotherapy experience chemotherapy-induced nausea and vomiting. Aromatherapy may reduce symptoms of nausea and vomiting in patients receiving chemotherapy for their cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT05319860.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVE:
I. To investigate the effect of aromatherapy inhalation on chemotherapy-induced nausea and vomiting (CINV) and the use of antiemetics among patients with cancer receiving moderate to high emetogenic outpatient chemotherapy regimens.
SECONDARY OBJECTIVE:
I. To investigate the effect of aromatherapy inhalation on resilience, psychological distress symptoms (e.g., stress, anxiety, and depression), and quality of life among patients with cancer receiving moderate to high emetogenic chemotherapy regimens outpatient.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive standard of care antiemetic medication over the course of 3 or more standard of care chemotherapy cycles.
ARM II: Patients receive standard of care antiemetic medication and use an aromatherapy inhaler as needed over the course of 3 or more standard of care chemotherapy cycles.
Trial PhasePhase II
Trial Typesupportive care
Lead OrganizationUniversity of Miami Miller School of Medicine-Sylvester Cancer Center
Principal InvestigatorDebbie Anglade
